Helper T cell anergy: From biochemistry to cancer pathophysiology and therapeutics

Journal of Molecular Medicine

Volumn 78, Issue 12, 2001, Pages 673-683

  Appleman, Leonard J ^a   Tzachanis, Dimitrios ^a   Grader Beck, Thomas ^a   Van Puijenbroek, Andre A F L ^a   Boussiotis, Vassiliki A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Anergy; Costimulation, T cells; Tolerance

Indexed keywords

ANIMAL CELL; ANTIGENICITY; CALCIUM CELL LEVEL; CELL CYCLE S PHASE; CLONAL ANERGY; COMPLEX FORMATION; HELPER CELL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; RECEPTOR UPREGULATION; REVIEW; SECOND MESSENGER; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CLONAL ANERGY; CYCLIC AMP; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; IMMUNE TOLERANCE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR SUPPRESSOR PROTEINS;

EID: 0034464266     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000180     Document Type: Review

References (105)

1. A cell culture model for T lymphocyte clonal anergy
2. T cell clonal anergy
3. The anatomy of T-cell activation and tolerance
4. Mechanisms of peripheral T cell deletion: Anergized T cells are Fas resistant but undego proliferation-associated apoptosis
5. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance
6. Induction of T cell clonal anergy results in resistance, whereas CD28 mediated costimulation primes for susceptibility to Fas and Bax mediated programmed cell death
7. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo
8. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance
9. Reduced CD3-mediated protein tyrosine phosphorylation in anergic CD4+ and CD8+ T cells
10. Altered protein tyrosine phosphorylation in anergic Th1 cells
11. Anergic T-lymphocyte clones have altered inositol phosphate, calcium and tyrosine kinase signaling pathways
12. Defective TCR-mediated signaling in anergic T cells
13. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen
14. Transgenic mice expressing both B7 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T lymphocyte unresponsiveness
15. Expression of functional B7 and CTLA4 on rheumatoid synovial T cells
16. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
17. CD4+ T cells tolerized ex-vivo to host alloantigen by anti-CD40 ligand (CD40L: CD154) antibody lose their graft-versus-host lethality capacity but retain normal antigen responses
18. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule
19. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg
20. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
21. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecule CD28 and CTLA-4
22. + T cells by B7-transfected melanoma cells
23. T-cell clonal anergy
24. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
25. The role of B7-1/B7-2: CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
26. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo
27. Treatment of murine lupus with CTLA4Ig
28. Soluble CTLA-4 can suppress autoantibody production and elicit long term responsiveness in a novel transgenic model
29. Molecular and biological characterization of a murine ligand for CD40
30. The CD40 antigen and its ligand
31. In the absence of CD40 signals B cells are tolerogenic
32. Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice
33. Clonal anergy induced in mature Vβ6+ T lymphocytes on immunizing MLs-1b mice with Mls-1a expressing cells
34. In vivo induction of anergy in peripheral Vβ8+ T cells by staphylococcal enterotoxin B
35. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
36. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells
37. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role of IL-10 in induction of tolerance
38. Induction of tolerance by IL-10-treated dendritic cells
39. TGF-beta 1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naive and primed T cells
40. Partial T cell signaling: Altered phospho-ζ and lack of Zap70 recruitment in APL-induced T cell anergy
41. ζ phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists
42. Differential association of protein tyrosine kinases with T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation
43. A CD4+ T-cell subset inhibits antigen-specific T cell responses and prevents colitis
44. IL-10 producing T cells suppress immune responses in anergic tuberculosis patients
45. Tolerance of T-cell clones is associated with membrane antigen changes
46. fyn
47. Induction of the increased fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A
48. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells
49. Blocked Ras activation in anergic CD4+ T cells
50. Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways
51. Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1
52. Differential induction of transcription factors that regulate the interleukin 2 gene during anergy induction and restimulation
53. Transactivation by AP-1 is a molecular target of T cell clonal anergy
54. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB and JunB in anergic T helper 1 cells
55. Identification of a zinc finger protein that inhibits IL-2 gene expression
56. Negative transcriptional regulation in anergic T cells
57. Multifactor cis-Dominant negative regulation of IL-2 gene expression in anergized T cells
58. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy
59. The role of cell division in the induction of clonal anergy
60. A ras-related gene with transformation suppressor activity
61. Molecular cloning of a GTPase activating protein specific for the Krev-1 protein p21rap1
62. A cyclin-dependent kinase inhibitor, Dacapo, is necessary for timely exit from the cell cycle during Drosophila embryogenesis
63. CD28 costimulation mediates T cell expansion via IL-2 independent and IL-2 dependent regulation of cell cycle progression
64. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation
65. Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin
66. p27kip1 functions as an anergy factor inhibiting IL-2 transcription and clonal expansion of alloreactive human and murine helper T lymphocytes
67. Degradation of the cyclin-dependent-kinase inhibitor p27kip1 is instigated by Jab1
68. G1 phase progression: Cyclin on cue
69. Inhibitors of mammalian G1 cyclin-dependent kinases
70. The retinoblastoma protein and cell cycle control
71. Cyclin E-cdk2 is a regulator of p27kip1
72. Induction of p27kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
73. Ras activity in G1 phase required for p27kip1 downregulation, passage through the restriction point and entry into S phase in growth factor-stimulated NIH-3T3 fibroblasts
74. Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells
75. Ras signaling linked to the cell-cycle machinery by the retinoblastoma protein
76. CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line
77. fyn regulate CD28 binding to phosphotidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, T cell-specific protein tyrosine kinase ITK: Implications for T cell costimulation
78. ras
79. Inactivation of a cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes
80. Models of T cell anergy: Is there a common molecular mechanism?
81. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
82. B7 but not ICAM-1 costimulation prevents the induction of human alloantigen specific tolerance
83. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
84. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes
85. cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase and holoenzyme
86. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
87. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 Cip1
88. A novel inhibitor of cyclin-cdk activity detected in transforming growth factor β-arrested epithelial cells
89. Translational control of p27kip1 accumulation during the cell cycle
90. p27kip1 a cyclin-cdk inhibitor, links transforming factor-b and contact inhibition to cell cycle arrest
91. Inhibition of cell cycle progression by rapamycin induces T cell clonal an-ergy even in the presence of costimulation
92. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
93. Combined costimulation blockade plus rapamycin but not cyclo-sporin produces permanent engraftment
94. Prolonged survival without post-transplant immunosuppression in a large animal model
95. Increase of endogenous cyclic AMP recapitulates functional and biochemical properties of T cell anergy
96. Complete blockade of B7 family mediated costimulation is necessary to induce alloantigen specific anergy: A method to ameliorate graft versous host disease and extend the donor pool
97. Tob, a novel Tob/BTG1 family member that associates with the CCR4 transcriptional regulatory complex is selectively expressed in anergic T cells and inhibits IL-2 transcription
98. Blockade of B7/CD28 pathway results in the generation of alternatively activated macrophages
99. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
100. + T-cell tolerance to T-cell priming through in vivo ligation of CD40
101. Characterization of circulating T cells specific for tumor associated antigens in melanoma patients
102. Split functional and signaling properties of splenic T cells in patients with marginal cell lymphoma
103. Biochemical markers of anergy in vitro correlate with prevention of GVHD and tolerance in vivo
104. Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor
105. Transplantation of anergic histoincompatible bone marrow allografts